US Pharma MarketingExclusive: RegCell gets $66M boost to take Nobel-winning Tregs into clinic
RegCell raises $44M Series A led by Playground Global to advance Treg cell therapies for autoimmune diseases, targeting pemphigus vulgaris and liver conditions by 2029. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
For nearly 50 years, Shimon Sakaguchi has been studying and working on regulatory T cells, figuring out how the immune system "governs itself."
Now, the Nobel laureate's decade-old biotech RegCell is gearing up for clinical ...
Source: Endpoints News